Topic 0th:
	treatment 0.02325581395348837
	mg/m2 0.02325581395348837
	disease 0.01758366420873511
	investigation 0.01191151446398185
	over 0.01191151446398185
	hours 0.01191151446398185
	p-akt 0.006239364719228588
	p-mtor 0.006239364719228588
	p-stat3 0.006239364719228588
	positive 0.006239364719228588
	response/resistance 0.006239364719228588
	combined 0.006239364719228588
	tumor 0.006239364719228588
	initial 0.006239364719228588
	then 0.006239364719228588
Topic 1th:
	1 0.02892796369824163
	upregulation 0.01758366420873511
	dose 0.01191151446398185
	actively 0.01191151446398185
	underwent 0.01191151446398185
	) 0.01191151446398185
	7 0.01191151446398185
	constitutive 0.01191151446398185
	compartments 0.01191151446398185
	patients 0.006239364719228588
	alone 0.006239364719228588
	inhibitor 0.006239364719228588
	(mtor) 0.006239364719228588
	recurrent 0.006239364719228588
	one 0.006239364719228588
Topic 2th:
	treatment 0.05279665446941975
	inhibitor 0.026659696811291163
	patient's 0.021432305279665442
	tumor 0.01620491374803973
	resistance 0.01097752221641401
	our 0.01097752221641401
	assessment 0.01097752221641401
	through 0.01097752221641401
	pilot 0.005750130684788291
	[4] 0.005750130684788291
	duration 0.005750130684788291
	drugs 0.005750130684788291
	addition 0.005750130684788291
	another 0.005750130684788291
	(igf1r)-targeted 0.005750130684788291
Topic 3th:
	response 0.030484160191273157
	combination 0.030484160191273157
	activation 0.012552301255230125
	temsirolimus 0.012552301255230125
	resection 0.012552301255230125
	near 0.012552301255230125
	signal-regulated 0.00657501494321578
	scoring 0.00657501494321578
	metastatic 0.00657501494321578
	performed 0.00657501494321578
	igf1r 0.00657501494321578
	treatment 0.00657501494321578
	(thr202/tyr204) 0.00657501494321578
	after 0.00657501494321578
	high-dose 0.00657501494321578
Topic 4th:
	sarcoma 0.07146753955264593
	receptor 0.01691216584833606
	showed 0.01691216584833606
	may 0.011456628477905073
	he 0.011456628477905073
	his 0.011456628477905073
	there 0.011456628477905073
	[20] 0.011456628477905073
	1 0.006001091107474086
	pathway 0.006001091107474086
	(igf1r) 0.006001091107474086
	two 0.006001091107474086
	antibody 0.006001091107474086
	inhibitor 0.006001091107474086
	upregulation 0.006001091107474086
Topic 5th:
	igf1r 0.06190741773563859
	however 0.022866703848298937
	who 0.01728945900725042
	md 0.01728945900725042
	treated 0.011712214166201896
	probes 0.011712214166201896
	may 0.011712214166201896
	r1507 0.011712214166201896
	lung 0.011712214166201896
	rheb 0.011712214166201896
	factor 0.006134969325153374
	mechanisms 0.006134969325153374
	antibody 0.006134969325153374
	tumor 0.006134969325153374
	combination 0.006134969325153374
Topic 6th:
	months 0.03460011344299489
	2 0.01758366420873511
	been 0.01758366420873511
	[nuclear] 0.01191151446398185
	might 0.01191151446398185
	shown 0.01191151446398185
	patients) 0.01191151446398185
	c) 0.01191151446398185
	s6k 0.01191151446398185
	signal-regulated 0.006239364719228588
	nestin 0.006239364719228588
	202/tyr 0.006239364719228588
	2+ 0.006239364719228588
	*maximum 0.006239364719228588
	signal) 0.006239364719228588
Topic 7th:
	signaling 0.03188708834291688
	targeted 0.026659696811291163
	nodule 0.021432305279665442
	combined 0.01620491374803973
	no 0.01097752221641401
	treatment 0.01097752221641401
	activation 0.01097752221641401
	trial 0.01097752221641401
	insulin-like 0.005750130684788291
	specimens 0.005750130684788291
	kinase 0.005750130684788291
	*maximum 0.005750130684788291
	performed 0.005750130684788291
	two 0.005750130684788291
	antibody 0.005750130684788291
Topic 8th:
	activation 0.07069616837560712
	response 0.03831624392876416
	resistance 0.022126281705342685
	morphoproteomic 0.01672962763086886
	well 0.011332973556395036
	regression 0.011332973556395036
	x400 0.011332973556395036
	receptor 0.005936319481921209
	2 0.005936319481921209
	mechanisms 0.005936319481921209
	then 0.005936319481921209
	explain 0.005936319481921209
	inhibition 0.005936319481921209
	results 0.005936319481921209
	suggests 0.005936319481921209
Topic 9th:
	after 0.08328411104548139
	no 0.01831069108092144
	[12] 0.012404016538688717
	showing 0.012404016538688717
	panel: 0.012404016538688717
	growth 0.006497341996455995
	705) 0.006497341996455995
	original 0.006497341996455995
	recurrent 0.006497341996455995
	remarkable 0.006497341996455995
	surgery 0.006497341996455995
	combinations 0.006497341996455995
	appropriate 0.006497341996455995
	dramatic 0.006497341996455995
	university 0.006497341996455995
Topic 10th:
	expression 0.053123175715119667
	therapy 0.02393461762988908
	1 0.018096906012842966
	md 0.012259194395796848
	plasmalemmal 0.012259194395796848
	pulmonary 0.012259194395796848
	(specimen 0.012259194395796848
	morphoproteomic 0.00642148277875073
	patient 0.00642148277875073
	no 0.00642148277875073
	(no 0.00642148277875073
	small 0.00642148277875073
	igf1r 0.00642148277875073
	assessed 0.00642148277875073
	705) 0.00642148277875073
Topic 11th:
	tumor 0.047563123899001754
	6 0.0182031708749266
	patient 0.012331180270111567
	responses 0.012331180270111567
	both 0.012331180270111567
	after 0.012331180270111567
	studies 0.012331180270111567
	sarcoma 0.0064591896652965355
	graded 0.0064591896652965355
	small 0.0064591896652965355
	(ser2448) 0.0064591896652965355
	guide 0.0064591896652965355
	[3] 0.0064591896652965355
	cycle 0.0064591896652965355
	rational 0.0064591896652965355
Topic 12th:
	resistance 0.02352266207687894
	then 0.02352266207687894
	antibody 0.012048192771084336
	initial 0.012048192771084336
	second 0.012048192771084336
	disease 0.012048192771084336
	biopsy 0.012048192771084336
	1?5 0.012048192771084336
	time 0.012048192771084336
	akt 0.012048192771084336
	no 0.006310958118187034
	scale 0.006310958118187034
	performed 0.006310958118187034
	immunohistochemical 0.006310958118187034
	igf1r-antibody 0.006310958118187034
Topic 13th:
	number 0.013879709187045603
	response 0.013879709187045603
	their 0.013879709187045603
	responded 0.013879709187045603
	mechanisms 0.007270323859881031
	plus 0.007270323859881031
	(ser2448) 0.007270323859881031
	combination 0.007270323859881031
	activated 0.007270323859881031
	radiation 0.007270323859881031
	morphoproteomics 0.007270323859881031
	another 0.007270323859881031
	experience 0.007270323859881031
	data 0.007270323859881031
	follows: 0.007270323859881031
Topic 14th:
	igf1r 0.08831596269884806
	antibody 0.02249040043883708
	first 0.017004936917169502
	line 0.01151947339550192
	( 0.01151947339550192
	panel 0.01151947339550192
	nuclei 0.01151947339550192
	p-akt 0.006034009873834339
	ewing's 0.006034009873834339
	treatment 0.006034009873834339
	upregulation 0.006034009873834339
	seen 0.006034009873834339
	resistant 0.006034009873834339
	malignant 0.006034009873834339
	stem 0.006034009873834339
Topic 15th:
	figure 0.01831069108092144
	both 0.012404016538688717
	radiation 0.012404016538688717
	interval 0.012404016538688717
	currently 0.012404016538688717
	[21] 0.012404016538688717
	depicting 0.012404016538688717
	profiling 0.006497341996455995
	patient 0.006497341996455995
	cd99 0.006497341996455995
	advanced 0.006497341996455995
	resistance 0.006497341996455995
	single-agent 0.006497341996455995
	applied 0.006497341996455995
	combination 0.006497341996455995
Topic 16th:
	tumor 0.02325581395348837
	analysis 0.02325581395348837
	inhibition 0.02325581395348837
	followed 0.01758366420873511
	probes 0.01758366420873511
	phase 0.01758366420873511
	showing 0.01191151446398185
	endothelial 0.01191151446398185
	b) 0.01191151446398185
	(specimen 0.01191151446398185
	stat3 0.006239364719228588
	thr 0.006239364719228588
	p-akt 0.006239364719228588
	ewing's 0.006239364719228588
	therapy 0.006239364719228588
Topic 17th:
	temsirolimus 0.024654239326518338
	study 0.018641010222489478
	ewing's 0.012627781118460612
	trials 0.012627781118460612
	morphoproteomic 0.00661455201443175
	tumoral 0.00661455201443175
	immunohistochemical 0.00661455201443175
	seen 0.00661455201443175
	primary 0.00661455201443175
	understanding 0.00661455201443175
	combining 0.00661455201443175
	[4] 0.00661455201443175
	optimize 0.00661455201443175
	outset 0.00661455201443175
	below 0.00661455201443175
Topic 18th:
	antibody 0.023388476896748427
	metastatic 0.017683970336565887
	combined 0.017683970336565887
	been 0.017683970336565887
	(tyr 0.011979463776383342
	mtor 0.011979463776383342
	while 0.011979463776383342
	cd99 0.006274957216200799
	p-akt 0.006274957216200799
	small 0.006274957216200799
	perhaps 0.006274957216200799
	multimodal 0.006274957216200799
	plateau 0.006274957216200799
	clinical 0.006274957216200799
	mechanistically-diverse 0.006274957216200799
Topic 19th:
	resistance 0.022994952327537854
	patients 0.017386427369601793
	subsequently 0.017386427369601793
	continued 0.017386427369601793
	tumor 0.01177790241166573
	upregulation 0.01177790241166573
	torc1 0.01177790241166573
	[23] 0.01177790241166573
	treatment 0.0061693774537296695
	mtor 0.0061693774537296695
	both 0.0061693774537296695
	most 0.0061693774537296695
	been 0.0061693774537296695
	poor 0.0061693774537296695
	agents 0.0061693774537296695
Topic 20th:
	treated 0.01748448956570784
	mtor 0.01748448956570784
	sections 0.01748448956570784
	igf1r 0.011844331641285956
	emerged 0.011844331641285956
	early 0.011844331641285956
	ct 0.011844331641285956
	scan 0.011844331641285956
	profiling 0.006204173716864072
	insulin-like 0.006204173716864072
	receptor 0.006204173716864072
	stat3 0.006204173716864072
	2 0.006204173716864072
	signal) 0.006204173716864072
	**percentage 0.006204173716864072
Topic 21th:
	) 0.051911009697661145
	patients 0.02909298345693097
	mtor 0.017683970336565887
	primary 0.011979463776383342
	tumors 0.011979463776383342
	findings 0.011979463776383342
	( 0.011979463776383342
	1 0.006274957216200799
	pathway 0.006274957216200799
	(mtor) 0.006274957216200799
	suggests 0.006274957216200799
	understanding 0.006274957216200799
	trials 0.006274957216200799
	given 0.006274957216200799
	predicting 0.006274957216200799
Topic 22th:
	1's 0.013350286077558804
	advanced 0.006993006993006993
	we 0.006993006993006993
	understand 0.006993006993006993
	resistant 0.006993006993006993
	been 0.006993006993006993
	increasing 0.006993006993006993
	dosage 0.006993006993006993
	decreasing 0.006993006993006993
	agents 0.006993006993006993
	bedside 0.006993006993006993
	reported 0.006993006993006993
	responded 0.006993006993006993
	anderson 0.006993006993006993
	717454 0.006993006993006993
Topic 23th:
	followed 0.01758366420873511
	cells 0.01758366420873511
	3+ 0.01191151446398185
	detect 0.01191151446398185
	one 0.01191151446398185
	survival 0.01191151446398185
	activity 0.01191151446398185
	2448) 0.01191151446398185
	and/or 0.01191151446398185
	left 0.01191151446398185
	specimens 0.006239364719228588
	nestin 0.006239364719228588
	intensity 0.006239364719228588
	intensity) 0.006239364719228588
	tumor 0.006239364719228588
Topic 24th:
	tumor 0.049601959583588484
	recurrent 0.03735456215554194
	i 0.012859767299448866
	targeted 0.006736068585425597
	inhibitor: 0.006736068585425597
	cd99 0.006736068585425597
	(no 0.006736068585425597
	rapamycin 0.006736068585425597
	one 0.006736068585425597
	attained 0.006736068585425597
	refractory 0.006736068585425597
	loops 0.006736068585425597
	not 0.006736068585425597
	plos 0.006736068585425597
	examination 0.006736068585425597
Topic 25th:
	patient 0.012859767299448866
	developed 0.012859767299448866
	resistant 0.012859767299448866
	therefore 0.012859767299448866
	ct 0.012859767299448866
	lung 0.012859767299448866
	patients 0.006736068585425597
	initial 0.006736068585425597
	upregulation 0.006736068585425597
	inhibition 0.006736068585425597
	overall 0.006736068585425597
	addition 0.006736068585425597
	another 0.006736068585425597
	biological/clinical 0.006736068585425597
	anderson 0.006736068585425597
Topic 26th:
	sarcoma 0.01758366420873511
	p-mtor 0.01758366420873511
	mtor 0.01758366420873511
	he 0.01758366420873511
	available 0.01191151446398185
	patient 0.006239364719228588
	responses 0.006239364719228588
	mechanisms 0.006239364719228588
	then 0.006239364719228588
	one 0.006239364719228588
	approach 0.006239364719228588
	change 0.006239364719228588
	survival 0.006239364719228588
	[3] 0.006239364719228588
	cycle 0.006239364719228588
Topic 27th:
	phase 0.053924185798184726
	ewing's 0.03790710090763481
	iv 0.021890016017084887
	1) 0.016550987720234916
	sarcoma 0.011211959423384944
	fusion 0.011211959423384944
	insulin-like 0.0058729311265349705
	pathway 0.0058729311265349705
	combination 0.0058729311265349705
	relapsed 0.0058729311265349705
	primary 0.0058729311265349705
	analysis 0.0058729311265349705
	revealed 0.0058729311265349705
	our 0.0058729311265349705
	assessment 0.0058729311265349705
Topic 28th:
	ras/raf 0.023795705165409166
	(ser473) 0.017991874637260593
	sarcoma 0.012188044109112013
	growth 0.012188044109112013
	specimens 0.012188044109112013
	ewing's 0.012188044109112013
	assessed 0.012188044109112013
	staining 0.012188044109112013
	started 0.012188044109112013
	morphoproteomic 0.006384213580963436
	(plasmalemmal) 0.006384213580963436
	p-erk 0.006384213580963436
	p-mtor 0.006384213580963436
	ser2448[nuclear] 0.006384213580963436
	performed 0.006384213580963436
Topic 29th:
	nestin 0.013100436681222707
	using 0.013100436681222707
	not 0.013100436681222707
	within 0.013100436681222707
	akt 0.013100436681222707
	sarcoma 0.006862133499688085
	pretreatment 0.006862133499688085
	metastatic 0.006862133499688085
	igf1r 0.006862133499688085
	(thr202/tyr204) 0.006862133499688085
	initial 0.006862133499688085
	remarkable 0.006862133499688085
	after 0.006862133499688085
	signatures 0.006862133499688085
	currently 0.006862133499688085
Topic 30th:
	patient 0.03982052720134604
	followed 0.028603477285473917
	disease 0.028603477285473917
	rapamycin 0.01177790241166573
	after 0.01177790241166573
	chemotherapy 0.01177790241166573
	treated 0.0061693774537296695
	2 0.0061693774537296695
	factor 0.0061693774537296695
	both 0.0061693774537296695
	showed 0.0061693774537296695
	analysis 0.0061693774537296695
	more 0.0061693774537296695
	agents 0.0061693774537296695
	heterogeneity 0.0061693774537296695
Topic 31th:
	she 0.02352266207687894
	positive 0.01778542742398164
	tumors 0.01778542742398164
	different 0.01778542742398164
	biopsy 0.01778542742398164
	initial 0.012048192771084336
	both 0.012048192771084336
	+/�?? 0.006310958118187034
	>50% 0.006310958118187034
	small 0.006310958118187034
	our 0.006310958118187034
	using 0.006310958118187034
	through 0.006310958118187034
	remains 0.006310958118187034
	bedside 0.006310958118187034
Topic 32th:
	response 0.018641010222489478
	combination 0.018641010222489478
	1 0.012627781118460612
	inhibitor 0.012627781118460612
	emerged 0.012627781118460612
	lungs 0.012627781118460612
	a) 0.012627781118460612
	kinase/extracellular 0.00661455201443175
	pathway 0.00661455201443175
	2 0.00661455201443175
	therapies 0.00661455201443175
	ewing's 0.00661455201443175
	pilot 0.00661455201443175
	mammalian 0.00661455201443175
	more 0.00661455201443175
Topic 33th:
	therapy 0.06368330464716006
	patient 0.02352266207687894
	0 0.01778542742398164
	resistance 0.01778542742398164
	(erk) 0.012048192771084336
	antibody 0.012048192771084336
	plus 0.012048192771084336
	[17] 0.012048192771084336
	days) 0.012048192771084336
	exposure 0.012048192771084336
	(igf-1r) 0.006310958118187034
	2+ 0.006310958118187034
	graded 0.006310958118187034
	scale 0.006310958118187034
	**percentage 0.006310958118187034
Topic 34th:
	alone 0.02325581395348837
	ews-fli1 0.02325581395348837
	1 0.01191151446398185
	p-erk 0.01191151446398185
	number 0.01191151446398185
	tumor 0.01191151446398185
	combination 0.01191151446398185
	previously 0.01191151446398185
	nuclei 0.01191151446398185
	last 0.01191151446398185
	receptor 0.006239364719228588
	pathway 0.006239364719228588
	mtorc2 0.006239364719228588
	(1+) 0.006239364719228588
	0 0.006239364719228588
Topic 35th:
	1 0.06055646481178396
	sarcoma 0.011456628477905073
	receptor 0.011456628477905073
	response 0.011456628477905073
	left 0.011456628477905073
	time 0.011456628477905073
	reveal: 0.011456628477905073
	substrate 0.011456628477905073
	table 0.006001091107474086
	ewing 0.006001091107474086
	* 0.006001091107474086
	ser 0.006001091107474086
	<10% 0.006001091107474086
	positive 0.006001091107474086
	despite 0.006001091107474086
Topic 36th:
	therapy 0.03346132748217224
	response 0.02797586396050466
	we 0.017004936917169502
	study 0.017004936917169502
	cells 0.017004936917169502
	weeks 0.01151947339550192
	mechanism 0.01151947339550192
	no 0.006034009873834339
	tyr 0.006034009873834339
	705 0.006034009873834339
	scoring 0.006034009873834339
	antibody 0.006034009873834339
	combined 0.006034009873834339
	(ser473) 0.006034009873834339
	using 0.006034009873834339
Topic 37th:
	(ser 0.035525852972212446
	cytoplasmic 0.03200844178684488
	p-akt 0.02849103060147731
	nuclear 0.02849103060147731
	mtorc2 0.02497361941610974
	nestin 0.02497361941610974
	pathway 0.021456208230742173
	p-mtor 0.021456208230742173
	p-stat3 0.021456208230742173
	specimen 0.021456208230742173
	expression 0.021456208230742173
	consistent 0.017938797045374603
	(tyr 0.014421385860007033
	but 0.014421385860007033
	tumoral 0.010903974674639464
Topic 38th:
	center 0.0194601381042059
	cancer 0.013182674199623351
	frames 0.013182674199623351
	patient 0.006905210295040804
	young 0.006905210295040804
	[3] 0.006905210295040804
	peripheral 0.006905210295040804
	cells 0.006905210295040804
	possibly 0.006905210295040804
	identify 0.006905210295040804
	therefore 0.006905210295040804
	i) 0.006905210295040804
	(study 0.006905210295040804
	previously 0.006905210295040804
	twenty-four 0.006905210295040804
Topic 39th:
	patient 0.07559145989613386
	pathway 0.02365839584535487
	history 0.02365839584535487
	shows 0.01788805539526832
	neural 0.01788805539526832
	factor-1 0.006347374495095211
	(high 0.006347374495095211
	nuclei. 0.006347374495095211
	factor 0.006347374495095211
	performed 0.006347374495095211
	emerged 0.006347374495095211
	analysis 0.006347374495095211
	merits 0.006347374495095211
	further 0.006347374495095211
	guide 0.006347374495095211
Topic 40th:
	tumor 0.04301646309081253
	tumoral 0.01646309081253319
	activity 0.01646309081253319
	he 0.01646309081253319
	ewing's 0.011152416356877323
	study 0.011152416356877323
	activated 0.011152416356877323
	clinical 0.011152416356877323
	tumors 0.011152416356877323
	nj) 0.011152416356877323
	10.1371/journal.pone.0018424.t001 0.005841741901221455
	(1�??3+) 0.005841741901221455
	1+ 0.005841741901221455
	(0�??3+) 0.005841741901221455
	metastatic 0.005841741901221455
Topic 41th:
	original 0.02892796369824163
	recurrent 0.02892796369824163
	ewing's 0.02325581395348837
	noted 0.01758366420873511
	+: 0.01191151446398185
	pain 0.01191151446398185
	p-akt 0.006239364719228588
	metastatic 0.006239364719228588
	pilot 0.006239364719228588
	combined 0.006239364719228588
	(thr202/tyr204) 0.006239364719228588
	subsequent 0.006239364719228588
	strategies 0.006239364719228588
	however 0.006239364719228588
	deciding 0.006239364719228588
Topic 42th:
	( 0.03402119353039598
	two 0.022866703848298937
	igf1r 0.01728945900725042
	(imca12+ 0.011712214166201896
	patient 0.006134969325153374
	204 0.006134969325153374
	[nuclear] 0.006134969325153374
	intensity 0.006134969325153374
	therapy 0.006134969325153374
	applied 0.006134969325153374
	p-erk1/2 0.006134969325153374
	705) 0.006134969325153374
	then 0.006134969325153374
	both 0.006134969325153374
	while 0.006134969325153374
Topic 43th:
	2 0.03383250138657792
	showed 0.022739877981142537
	pathways 0.011647254575707155
	scan 0.011647254575707155
	panel 0.011647254575707155
	/erk 0.011647254575707155
	morphoproteomic 0.006100942872989462
	insulin-like 0.006100942872989462
	* 0.006100942872989462
	(2+) 0.006100942872989462
	we 0.006100942872989462
	therapy 0.006100942872989462
	perhaps 0.006100942872989462
	further 0.006100942872989462
	[2] 0.006100942872989462
Topic 44th:
	pathways 0.022126281705342685
	lung 0.022126281705342685
	pathway 0.01672962763086886
	response 0.01672962763086886
	patients 0.011332973556395036
	revealed 0.011332973556395036
	4 0.011332973556395036
	without 0.011332973556395036
	morphoproteomic 0.005936319481921209
	sarcoma 0.005936319481921209
	growth 0.005936319481921209
	number 0.005936319481921209
	better 0.005936319481921209
	therapy 0.005936319481921209
	both 0.005936319481921209
Topic 45th:
	disease 0.0303030303030303
	six 0.024361259655377297
	responses 0.012477718360071301
	metastatic 0.012477718360071301
	consent 0.012477718360071301
	over 0.012477718360071301
	protein 0.012477718360071301
	mtorc2 0.006535947712418301
	no 0.006535947712418301
	cd99 0.006535947712418301
	473 0.006535947712418301
	results 0.006535947712418301
	benefit 0.006535947712418301
	1) 0.006535947712418301
	given 0.006535947712418301
Topic 46th:
	sarcoma 0.036461446503287503
	igf1r 0.030484160191273157
	therapy 0.024506873879258814
	infusion 0.024506873879258814
	3 0.01852958756724447
	resistance 0.012552301255230125
	signals 0.012552301255230125
	insulin 0.012552301255230125
	kinase 0.00657501494321578
	� 0.00657501494321578
	mammalian 0.00657501494321578
	treatment 0.00657501494321578
	(tyr 0.00657501494321578
	erk 0.00657501494321578
	80% 0.00657501494321578
Topic 47th:
	patients 0.0727519204699503
	ewing's 0.06371441482150926
	igf1r 0.03660189787618617
	advanced 0.02756439222774514
	pathway 0.023045639403524623
	sarcoma 0.01852688657930411
	present 0.01852688657930411
	2 0.014008133755083597
	anderson 0.014008133755083597
	two 0.009489380930863081
	both 0.009489380930863081
	progressed 0.009489380930863081
	pet/ct 0.009489380930863081
	table 0.004970628106642567
	profiling 0.004970628106642567
Topic 48th:
	mtor 0.08689390302448392
	inhibitor 0.08209313490158425
	nestin 0.029284685549687946
	complex 0.014882381180988958
	target 0.010081613058089293
	then 0.010081613058089293
	[17] 0.010081613058089293
	figure 0.010081613058089293
	total 0.010081613058089293
	neural 0.010081613058089293
	ewing's 0.00528084493518963
	combined 0.00528084493518963
	developed 0.00528084493518963
	detect 0.00528084493518963
	p-erk1/2 0.00528084493518963
Topic 49th:
	i 0.022367703218767045
	study 0.01691216584833606
	she 0.01691216584833606
	clinical 0.011456628477905073
	different 0.011456628477905073
	received 0.011456628477905073
	d) 0.011456628477905073
	morphoproteomic 0.006001091107474086
	** 0.006001091107474086
	intensity 0.006001091107474086
	responses 0.006001091107474086
	advanced 0.006001091107474086
	immunohistochemical 0.006001091107474086
	(ser2448) 0.006001091107474086
	original 0.006001091107474086
